Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer
Authors
Keywords
-
Journal
Medical Molecular Morphology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-07-29
DOI
10.1007/s00795-023-00367-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical and histopathological effects of neoadjuvant intra-arterial chemoradiotherapy with cisplatin in combination with oral S-1 on stage III and IV oral cancer
- (2022) Kazushige Koike et al. Oral Surgery Oral Medicine Oral Pathology Oral Radiology
- Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics
- (2022) Mitesh Dwivedi et al. Heliyon
- Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis
- (2021) Jerry Polesel et al. Frontiers in Oncology
- Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy
- (2020) Takaaki Tsuchiya et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Mechanisms regulating PD-L1 expression on tumor and immune cells
- (2019) Shuming Chen et al. Journal for ImmunoTherapy of Cancer
- Chemoradiotherapy using retrograde superselective intra-arterial infusion for tongue cancer: Analysis of therapeutic results in 118 cases
- (2018) Kenji Mitsudo et al. ORAL ONCOLOGY
- Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma
- (2018) Yuki Fukushima et al. RADIOTHERAPY AND ONCOLOGY
- Clinical outcomes of retrograde intra-arterial chemotherapy concurrent with radiotherapy for elderly oral squamous cell carcinoma patients aged over 80 years old
- (2017) Yuichiro Hayashi et al. Radiation Oncology
- Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy
- (2017) Panagiotis Balermpas et al. OncoImmunology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
- (2016) Hye Ryun Kim et al. Scientific Reports
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- Risk Stratification of Early Stage Oral Tongue Cancers Based on HPV Status and p16 Immunoexpression
- (2014) Vijayalakshmi Ramshankar et al. Asian Pacific Journal of Cancer Prevention
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- Outcomes of squamous cell cancer of the oral tongue managed at the princess margaret hospital
- (2012) David P. Goldstein et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Organ Preservation With Daily Concurrent Chemoradiotherapy Using Superselective Intra-Arterial Infusion via a Superficial Temporal Artery for T3 and T4 Head and Neck Cancer
- (2010) Kenji Mitsudo et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Intra-arterial chemoradiotherapy for locally advanced oral cavity cancer: analysis of therapeutic results in134 cases
- (2008) N Fuwa et al. BRITISH JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started